2m 2m 2m 2m 2m 2m 2m
- $2.1MMarket Cap
- N/A1-Year Change
- Medical DevicesIndustry
PHAOS TECH-A (POAS)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Phaos Technology Holdings (Cayman) Limited Provides Updated Response to Unusual Market Action
Phaos Technology Holdings (NYSE American: POAS) disclosed unusual trading activity in its Class A ordinary shares on February 13 and 17, 2026. The company stated it has made inquiries but cannot determine corrective actions at this time, and confirmed no material business developments or other factors explain the market activity.
02/19/2026, 5:00 AM • GlobeNewswire
Phaos Technology Announces Closing of Initial Public Offering
Phaos Technology Holdings completed its initial public offering, raising $10.8 million by selling 2.7 million class A ordinary shares at $4.00 per share on the NYSE American under the ticker POAS.
11/14/2025, 2:41 PM • Benzinga
Phaos Technology Announces Closing of Initial Public Offering
Phaos Technology Holdings completed its initial public offering of 2,700,000 class A ordinary shares at $4.00 per share, raising $10.8 million. The company's shares began trading on NYSE American under the ticker 'POAS' on November 13, 2025.
11/14/2025, 2:41 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 08/21/2026
Company Profile
Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore. The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation. It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization. In addition, the company offers software. The company serves manufacturing companies; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.
Key Executives
- Minghui Hong
- Hong Loon Gan
- Hook Seng Beh
Current Ownership Distribution
- Other13.4M (97.75%)
- Institutions309,070 (2.25%)
- Mutual Funds0 (0.00%)
- Insiders0 (0.00%)